Literature DB >> 19377904

18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma.

Jeong Won Lee1, Keon Wook Kang, Sung-Hye Park, Sang Mi Lee, Jin Chul Paeng, June-Key Chung, Myung Chul Lee, Dong Soo Lee.   

Abstract

PURPOSE: The purpose of this study was to investigate the role of (18)F-fluorodeoxyglucose (FDG) PET in detecting high-grade meningioma and predicting the recurrence in patients with meningioma after surgical resection.
METHODS: Fifty-nine patients (27 men and 32 women) with intracranial meningioma who underwent preoperative FDG PET and subsequent surgical resection were enrolled. All patients underwent clinical follow-up for tumor recurrence with a mean duration of 34+/-20 months. The tumor to gray matter ratio (TGR) of FDG uptake was calculated and a receiver-operating characteristic (ROC) curve of the TGR was drawn to determine the cutoff value of the TGR for detection of high-grade meningioma. Further, univariate analysis with the log-rank test was performed to assess the predictive factors of meningioma recurrence.
RESULTS: The TGR in high-grade meningioma (WHO grade II and III) was significantly higher than that in low-grade ones (WHO grade I) (p=0.002) and significantly correlated with the MIB-1 labeling index (r=0.338, p=0.009) and mitotic count of the tumor (r=0.284, p=0.03). The ROC analysis revealed that the TGR of 1.0 was the best cutoff value for detecting high-grade meningioma with a sensitivity of 43%, specificity of 95%, and accuracy of 81%. Of 59 patients, 5 (9%) had a recurrent event. In the log-rank test, the TGR, MIB-1 labeling index, presence of brain invasion, and WHO grade were significantly associated with tumor recurrence. The cumulative recurrence-free survival rate of patients with a TGR of 1.0 or less was significantly higher than that of patients with a TGR of more than 1.0 (p=0.0003)
CONCLUSION: FDG uptake in meningioma was the significant predictive factor of tumor recurrence and significantly correlated with the proliferative potential of the tumor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19377904     DOI: 10.1007/s00259-009-1133-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  28 in total

Review 1.  PET imaging for differentiating recurrent brain tumor from radiation necrosis.

Authors:  Roland Hustinx; Michael Pourdehnad; Bruno Kaschten; Abass Alavi
Journal:  Radiol Clin North Am       Date:  2005-01       Impact factor: 2.303

2.  Glucose and methionine uptake and proliferative activity in meningiomas.

Authors:  T Iuchi; Y Iwadate; H Namba; K Osato; N Saeki; A Yamaura; Y Uchida
Journal:  Neurol Res       Date:  1999-10       Impact factor: 2.448

3.  11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy.

Authors:  Anca-Ligia Grosu; Wolfgang A Weber; Sabrina T Astner; Markus Adam; Bernd J Krause; Markus Schwaiger; Michael Molls; Carsten Nieder
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-06-09       Impact factor: 7.038

4.  O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study.

Authors:  W A Weber; H J Wester; A L Grosu; M Herz; B Dzewas; H J Feldmann; M Molls; G Stöcklin; M Schwaiger
Journal:  Eur J Nucl Med       Date:  2000-05

5.  Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET.

Authors:  June-Key Chung; Yu Kyeong Kim; Seok-ki Kim; Yong Jin Lee; Suntta Paek; Jeong Seok Yeo; Jae Min Jeong; Dong Soo Lee; Hee Won Jung; Myung Chul Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-02       Impact factor: 9.236

6.  Classic, atypical, and anaplastic meningioma: three histopathological subtypes of clinical relevance.

Authors:  H Maier; D Ofner; A Hittmair; K Kitz; H Budka
Journal:  J Neurosurg       Date:  1992-10       Impact factor: 5.115

Review 7.  Imaging gliomas with positron emission tomography and single-photon emission computed tomography.

Authors:  François Bénard; Jonathan Romsa; Roland Hustinx
Journal:  Semin Nucl Med       Date:  2003-04       Impact factor: 4.446

8.  The combination of mitotic and Ki-67 indices as a useful method for predicting short-term recurrence of meningiomas.

Authors:  Jun A Takahashi; Tetsuya Ueba; Nobuo Hashimoto; Yasuaki Nakashima; Naomi Katsuki
Journal:  Surg Neurol       Date:  2004-02

9.  Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study.

Authors:  G Di Chiro; J Hatazawa; D A Katz; H V Rizzoli; D J De Michele
Journal:  Radiology       Date:  1987-08       Impact factor: 11.105

Review 10.  Clinical applications of PET in oncology.

Authors:  Eric M Rohren; Timothy G Turkington; R Edward Coleman
Journal:  Radiology       Date:  2004-03-24       Impact factor: 11.105

View more
  27 in total

1.  68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate?

Authors:  Michael Sommerauer; Jan-Karl Burkhardt; Karl Frontzek; Elisabeth Rushing; Alfred Buck; Niklaus Krayenbuehl; Michael Weller; Niklaus Schaefer; Felix P Kuhn
Journal:  Neuro Oncol       Date:  2016-02-09       Impact factor: 12.300

2.  Clinical characteristics of meningiomas assessed by ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron-emission tomography.

Authors:  Hideyuki Arita; Manabu Kinoshita; Yoshiko Okita; Ryuichi Hirayama; Tadashi Watabe; Kayako Ishohashi; Noriyuki Kijima; Naoki Kagawa; Yasunori Fujimoto; Haruhiko Kishima; Eku Shimosegawa; Jun Hatazawa; Naoya Hashimoto; Toshiki Yoshimine
Journal:  J Neurooncol       Date:  2011-11-17       Impact factor: 4.130

3.  Management of meningeal neoplasms: meningiomas and hemangiopericytomas.

Authors:  Zanetta Lamar; Glenn J Lesser
Journal:  Curr Treat Options Oncol       Date:  2011-09

Review 4.  PET imaging in patients with meningioma-report of the RANO/PET Group.

Authors:  Norbert Galldiks; Nathalie L Albert; Michael Sommerauer; Anca L Grosu; Ute Ganswindt; Ian Law; Matthias Preusser; Emilie Le Rhun; Michael A Vogelbaum; Gelareh Zadeh; Frédéric Dhermain; Michael Weller; Karl-Josef Langen; Jörg C Tonn
Journal:  Neuro Oncol       Date:  2017-11-29       Impact factor: 12.300

Review 5.  Brain invasion in meningiomas-clinical considerations and impact of neuropathological evaluation: a systematic review.

Authors:  Benjamin Brokinkel; Katharina Hess; Christian Mawrin
Journal:  Neuro Oncol       Date:  2017-10-01       Impact factor: 12.300

6.  Imaging and diagnostic advances for intracranial meningiomas.

Authors:  Raymond Y Huang; Wenya Linda Bi; Brent Griffith; Timothy J Kaufmann; Christian la Fougère; Nils Ole Schmidt; Jöerg C Tonn; Michael A Vogelbaum; Patrick Y Wen; Kenneth Aldape; Farshad Nassiri; Gelareh Zadeh; Ian F Dunn
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

7.  A rare case of atypical skull base meningioma with perineural spread.

Authors:  Henry Walton; Simon Morley; Javier Alegre-Abarrategui
Journal:  J Radiol Case Rep       Date:  2015-12-31

Review 8.  Intracranial meningiomas of atypical (WHO grade II) histology.

Authors:  Leland Rogers; Mark Gilbert; Michael A Vogelbaum
Journal:  J Neurooncol       Date:  2010-08-26       Impact factor: 4.130

9.  Applying Amide Proton Transfer MR Imaging to Hybrid Brain PET/MR: Concordance with Gadolinium Enhancement and Added Value to [18F]FDG PET.

Authors:  Hongzan Sun; Jun Xin; Jinyuan Zhou; Zaiming Lu; Qiyong Guo
Journal:  Mol Imaging Biol       Date:  2018-06       Impact factor: 3.488

10.  Long-term evaluation of the effect of hypofractionated high-energy proton treatment of benign meningiomas by means of (11)C-L-methionine positron emission tomography.

Authors:  Mats Ryttlefors; Torsten Danfors; Francesco Latini; Anders Montelius; Erik Blomquist; Olafur Gudjonsson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-28       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.